Cardio Axis

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 4

CARDIO AXIS

Company Overview - Cardio Axis is a company based in India that specializes in the field of cardiovascular
health. They focus on developing and providing advanced technologies and solutions for diagnosing and
managing cardiovascular diseases. Their products and services typically include diagnostic tools, medical
devices, and potentially software solutions designed to improve cardiovascular care.

Incorporation - Cardio Axis was incorporated in 2016. The company focuses on advancing cardiovascular health
through innovative technologies and solutions. If you’re looking for more detailed information about their
history, products, or recent updates, their official website or press releases would be good sources to check.

Man behind the company - Dr. Rakesh H. Dube is indeed associated with Cardio Axis. He is the founder and
CEO of the company. Dr. Dube has a background in medicine and a strong focus on cardiovascular health,
driving the company's mission to innovate and provide advanced solutions in this field.

Products

1. Drug-Eluting Stents (DES) - Drug-eluting stents are used to keep arteries open after an angioplasty
procedure. They are coated with a medication that helps prevent the artery from re-narrowing.

2. PTCA Balloons - These balloons are used during percutaneous transluminal coronary angioplasty (PTCA)
procedures to dilate narrowed coronary arteries.

3. Accessories - A range of support tools and devices used in conjunction with stents and balloons.

4. Drug-Eluting Balloons (DEB) - Similar to drug-eluting stents, drug-eluting balloons deliver medication to the
artery wall while expanding it to treat blockages.

5. Structural Heart Devices - These products are designed to address structural heart diseases and
abnormalities through minimally invasive procedures.

Awards

 ICON OF EXCELLENCE - ECONOMIC TIMES, 2021


 DR. A.P.J ABDUL KALAM PROFESSIONAL EXCELLENCE AWARD, 2022
 ASIA PACIFIC EXCELLENCE AWARD, 2022
 HEALTHCARE PROFESSIONAL ACHIEVER OF THE YEAR AWARD - THE GLOBAL HEALTHCARE AWARDS,
2022
 WORLD RECORD HOLDER - HIGHEST UP RANKING IN INTERVENTIONAL CARDIOLOGY MARKET, 2022
 4TH POSITION AS PER CARDIOLOGICAL SOCIETY OF INDIA NATIONAL INTERVENTION COUNCIL, 2020

USP of the Company

1. Advanced cardiovascular solutions with pioneering products like the Everton Everolimus Eluting Stent
and Oasis Drug Eluting Balloon.
2. Leads in developing groundbreaking technologies, including Transcatheter Aortic Valve Implantation
(TAVI) systems.
3. Collaborates with top hospitals and global entities to enhance market presence and reach.
4. Committed to extending device life and improving patient outcomes with advanced, patented
technologies.

Top Hospital Collaborations

 Manipal Hospitals
 AMRI Hospitals
 Fortis Hospitals
 Lions Hospitals
 IVY Hospitals
Market and Industry

Cardio Axis's Total Addressable Market (TAM) includes the expanding coronary stent market and the rapidly
growing transcatheter aortic valve (TAV) market. In India, PTCA procedures are increasing by 16% annually,
offering significant opportunities for Cardio Axis amid strong domestic competition. Globally, the TAV market,
valued at USD 4.5 billion in 2022, is projected to reach USD 7.1 billion by 2026 with a 12.2% CAGR and is
expected to grow to USD 25.4 billion by 2033 at a 14.8% CAGR. In India, the TAV market is growing at 9%
annually with 236 centers performing about 2,445 procedures in 2023. The average price for a valve is
projected to be INR 5.5 lakhs by 2026, with costs ranging from INR 75,000 to INR 1 lakh, highlighting a
competitive landscape with both international and local players..

SWOT Analysis

Strengths Weakness

Focus on Longevity High R&D and Production Costs


Strategic Collaborations Relatively New Entrant
Strong Regulatory Compliance Dependence on Regulatory Approvals
Awards and Recognition
Innovative Product Portfolio
Opportunity Threat
Increasing Demand for Advanced Cardiac Solutions Intense Competition
Technological Advancements Regulatory Hurdles
Global Expansion Market Volatility
Expanding Market Technological Risks

Proposed Management

Name Qualification Designation

Mr. Phillip Winters Ohle hale Interventional Cardiology Clinical and Marketing Expert, CardioAxis
Experience of 15 years Corporation (TAVR Project)

Dr. WON-KEUN KIM MD, Ph.D MD, Ph.D. Expert in Structural Heart Projects, CardioAxis
Corporation (TAVI Valve Development)

Dr. Ashok Seth Padma Shri, Padma Chairman & Director, Fortis Escorts Heart Institute,
Vibhushan, Chairman & Delhi
Professor

Dr. Rajneesh Kapoor Chairman - Cardiology, Chairman of Interventional Cardiology, Medanta -


Interventional Cardiology Medicity Gurgaon
Experience

Product Portfolio

Product Description Location

Everton Drug Eluting Stent Everolimus Eluting Coronary Stent System CardioAxis Corporation
Pvt Ltd

Excalibur Legend Drug Everolimus Eluting Coronary Stent System with CardioAxis Corporation
Eluting Stent unique features Pvt Ltd
Oasis Drug Eluting Balloon Drug Eluting Balloon used for coronary CardioAxis Corporation
interventions Pvt Ltd

Sirolimus Coated Balloon Used for the treatment of ISR and Coronary CardioAxis Corporation
Artery Disease Pvt Ltd

Products to be launched

To Be Launched Description Location

APT Medical, China Exclusive Distribution Rights for India CardioAxis Corporation Pvt Ltd

Braidin Radial & Femoral Introducer Sheath To be launched in India

Angiopointer Hydrophilic Angiography Catheters To be launched in India

March PTCA Guiding Catheter To be launched in India

Note: APT Medical, China has conducted successful clinical trials for their products, including the Spherical Tip
NC Balloon Conqueror, with a 98.9% success rate.

Filled Patents

1. Puncture Needle
2. PTCA Balloon Inflation Device
3. PTCA Y-Connector Kit
4. PTFE Coated Angiography Wire
5. Manifolds
6. Pressure Lines
7. Guide Extension Catheter
8. Microcatheter
9. High Pressure NC Balloon
10. PTCA Guidewires

Financials

CARDIOAXIS 2023 2024 2025 2026 2027 2028 2029


CORPORATION
Sales 14 55.09 140 178 257 371 467
EBITDA 0.17 8 32 39 61 107 138
EBITDA % 1% 15% 23% 22% 24% 29% 29%
PAT 0.09 3 17 17 34 68 92
PAT % 1% 7% 12% 10% 13% 18% 20%
Networth 510 2,980 6,617 8,335 11,78 18,60 27,79
5 0 7
Long term Loan 0 1,599 1,984 1,875 1,597 1,287 976

Sales / Revenue Net worth


500 467 30,000 27,797
450
25,000
400 371
350 20,000 18,600
300 257
250 15,000
11,785
200 178
140 10,000 8,335
150 6,617
100 55 5,000 2,980
50 14 510
0 0
2023 2024 2025 2026 2027 2028 2029 2023 2024 2025 2026 2027 2028 2029

PAT & PAT Margins EBITDA & EBITDA Margins


100 92 25% 160 35%
90 138
140
80 20% 20% 29% 29% 30%
18% 120 107 25%
70 68
100 23% 22% 24%
60 15% 20%
50 13% 80
12%
34 15% 61 15%
40 10% 10% 60
30 7% 39 10%
17 17 40 32
20 5%
20 8 5%
10 4
0 0
0 0% 0% 0 1% 0%
2023 2024 2025 2026 2027 2028 2029 2023 2024 2025 2026 2027 2028 2029

PAT PAT % EBITDA EBITDA %

Proposal and Usage of Funds

The company is looking forward to raise INR 193 Cr towards capital over the period of next 30 months.

Sr No Particulars Financial Year Amount (INR)

1 Design, Design Freeze & Prototyping of TAVI 2024-25 53,00,00,000


Animal Studies
Inventory Purchase
R&D Machinery and Operations
Acquisition of Land at MIDC Nagpur (6 acres)

2 Construction of Factory Building 2025-26 Q2 onwards 63,00,00,000


Purchase of Machinery, Establishment of Clean Rooms
Euro MDR Certification
510K Certification

3 First in Man – 150 Patients (Min 75 Patients in Euro 2026-27 Q3 onwards 77,00,00,000
Territory)
Early Feasibility Study
CE Study and Certifications

TOTAL 193,00,00,000

You might also like